» Articles » PMID: 38869665

The Contribution of Second Primary Cancers to the Mortality of Patients with a First Primary Breast Cancer

Overview
Specialty Oncology
Date 2024 Jun 13
PMID 38869665
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Second primary cancers (SPCs) are estimated to affect nearly 5% of patients with breast cancer within 10 years of their diagnosis. This study aimed to estimate the contribution of SPCs to the mortality of patients with a breast first primary cancer (FPC).

Methods: A population-based cohort of 17,210 patients with a breast FPC diagnosed between 2000 and 2010 was followed for SPCs (31/12/2015) and vital status (30/06/2021). Patients diagnosed with an SPC (265 synchronous and 897 metachronous, ≤ 1 and > 1 year after the FPC, respectively) were matched (1:3, by five-year age group and year of breast FPC diagnosis) to those without an SPC and alive when the corresponding SPC was diagnosed.

Results: Significantly higher hazards of death were found among patients with an SPC [hazard ratio of 1.56, 95% confidence interval (CI) 1.29-1.89 for synchronous SPCs; and 2.85, 95%CI 2.56-3.17 for metachronous SPCs] compared to patients with a breast FPC only. Estimates were higher for synchronous lung, stomach, non-Hodgkin lymphoma and breast SPCs, and metachronous liver, stomach, ovary, lung, rectum, corpus uteri, colon, breast, and non-Hodgkin lymphoma SPCs. The 15-year cumulative mortality was 59.5% for synchronous SPCs and 68.7% for metachronous SPCs, which was higher than in patients with a breast FPC only (43.6% and 44.8%, respectively).

Conclusions: In Northern Portugal, patients with an SPC following a breast FPC have a higher mortality compared with patients with a breast FPC only.

References
1.
Maiz C, Silva F, Dominguez F, Galindo H, Camus M, Leon A . Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution. Ecancermedicalscience. 2020; 14:1005. PMC: 7039691. DOI: 10.3332/ecancer.2020.1005. View

2.
Pacheco-Figueiredo L, Antunes L, Bento M, Lunet N . Evaluation of the frequency of and survival from second primary cancers in North Portugal: a population-based study. Eur J Cancer Prev. 2013; 22(6):599-606. DOI: 10.1097/CEJ.0b013e32835f3bbc. View

3.
Rossi L, Stevens D, Pierga J, Lerebours F, Reyal F, Robain M . Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. PLoS One. 2015; 10(7):e0132853. PMC: 4516355. DOI: 10.1371/journal.pone.0132853. View

4.
. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005; 14(4):307-8. DOI: 10.1097/00008469-200508000-00002. View

5.
Wei J, Jiang Y, Shao Z . Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol. 2019; 24(8):934-940. DOI: 10.1007/s10147-019-01430-0. View